Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €7.38 EUR
Change Today +0.286 / 4.03%
Volume 3.7K
APS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:54 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

26 Landsdowne Street

Cambridge, MA 02139

United States

Phone: 617-494-0400

Fax: 617-494-8144

ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. Products and Product Candidates Iclusig (ponatinib) is an approved cancer medicine, which the company is in the process of commercializing in the United States, Europe and other territories for the treatment of certain patients with rare forms of leukemia. The company intends to continue to focus its commercial efforts in the United States and in 16 major European countries. In 2014, the company secured an exclusive agreement for the co-development and commercialization of Iclusig in Japan and nine other Asian countries with Otsuka Pharmaceutical Co., Ltd., or Otsuka. The company plans to initiate three new randomized clinical trials to evaluate Iclusig in earlier lines of treatment and potentially to expand its addressable market. Brigatinib (previously known as AP26113) is a most advanced drug candidate, which the company is in the process of developing for the treatment of certain patients with a form of non-small cell lung cancer (NSCLC). In 2014, brigatinib received a Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with ALK+ NSCLC who are resistant to crizotinib, and the company initiated a pivotal Phase 2 trial in these patients. The company is focused on securing a co-development and co-commercialization partnership for brigatinib. AP32788 is an internally discovered drug candidate. In 2014, the company nominated AP32788 for clinical development. The company is conducting studies necessary to support the filing of an investigational new drug application (IND). Licenses and Collaboration Agreements with Third Parties In 2014, the company entered into an agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the commercialization and co-development of Iclusig in Japan and nine other Asian countries. Under the terms of the agreement, the company would lead the completion of the Japanese New Drug Application (JNDA), for Iclusig, and based on plans, Otsuka would file in 2015 the JNDA on behalf of both companies for regulatory approval in resistant and intolerant CML and Ph+ALL. The countries that are included in the agreement are Japan, China, South Korea, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam. In 2007, the company entered into a collaboration agreement with Merck & Co., Inc. (Merck) for the joint global development, manufacture and commercialization of ridaforolimus for use in cancer. In 2005, the company entered into a license agreement with Medinol and in 2007 the company entered into a license agreement with ICON Medical Corp. (ICON) to develop and commercialize ridaforolimus-eluting stents and other medical devices to prevent restenosis, or reblockage, of injured vessels following interventions in which stents are used in conjunction with balloon angioplasty. Trademarks ARIAD, the ARIAD logo and Iclusig are the company’s registered trademarks. ARGENT is its trademark. Intellectual Property The company owns the following patents and patent applications for its product candidates: Iclusig, the company’s pan BCR-ABL inhibitor, is protected by composition of matter claims of U.S. Patent No. 8,114,874, which would expire on December 22, 2026, subject to a patent term adjustment, and corresponding international counterparts; Brigatinib (AP26113), the company’s investigational ALK inhibitor, is covered by composition of matter claims of a pending U.S. patent application; Ridaforolimus, the company’s mTOR inhibitor, is protected by composition of matter claims of U.S. Patent No. 7,091,213, which expires on February 3, 2023; and AP32788, the company’s oncology development candidate, is covered by composition of matter claims of a pending U.S. patent application. History ARIAD Pharmaceuticals, Inc. was founded in 1991.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APS:GR €7.38 EUR +0.286

APS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.04 USD +0.07
Array BioPharma Inc $5.81 USD +0.06
Evotec AG €3.38 EUR -0.029
Exelixis Inc $5.73 USD +0.19
Pfizer Ltd/India 2,190 INR +14.05
View Industry Companies
 

Industry Analysis

APS

Industry Average

Valuation APS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.0x
Price/Book 40.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit www.ariad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.